Privia Health Group Inc (PRVA) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Privia Health Group Inc stock $5.52, price $24.42, that is 77.4% below the price, quality 59 out of 100. Rating: strongly overvalued. Calculated from audited financials with 24 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.
How to read this chart
60‑month range $16.09 – $42.97 · fair‑value band $4.72 – $6.52 · the $24.42 price screens above the $5.52 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.
Follow Privia Health Group in your weekly email
Every Wednesday you see whether Privia Health Group is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Privia Health Group, Inc. operates as a national physician-enablement company in the United States. The company collaborates with physician practices, health plans, and health systems.
Show moreShow less
It also offers technology and population health tools to enhance providers' workflows; management services organization that enable providers to focus on their patients by reducing administrative work; and single-TIN medical group that facilitates negotiating power, clinical integration, and alignment of financial incentives.
In addition, the company operates accountable care organization, which engages patients, reduce inappropriate utilization, and enhance coordination and patient quality metrics to drive value-based care; and network for purchasers and payers that enable providers to connect across platform to better understand the holistic needs of each patient and connect with other providers to address individual medical needs.
The company was founded in 2007 and is headquartered in Arlington, Virginia.
Stock analysis
Privia Health Group Inc (PRVA) currently trades at $24.42, while our model-based Fair Value estimate is $5.52, 77% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of $21.79 per share, and 2 of the 24 models we run sit above the $24.42 price.
Bear case: the Asset-Based group reads lowest at $3.00, and 22 of the 24 models stay below the price. Data coverage for this calculation is medium.
Scenario range: $4.72 (bear) to $6.52 (bull), the price of $24.42 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 59/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Privia Health Group Inc reported revenue of $2.1B in FY2025 versus $966M in FY2021, a compound +21.7%/yr. Reported net income was $22.9M in FY2025.
Key figures
Market cap $3.2B Mid · P/E ratio 93.9 · P/S ratio 1.71 · EPS (TTM) $0.2600 · Net margin 1.4% · Return on equity 4.7% · Return on assets (EBIT) −5.6% (5-year average) · Operating margin 3.1%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 29 out of 100 (low confidence).
What moves the price
The last reported earnings sit well below what analysts expect (earnings in transition, for example after write-downs or an earnings dip); whether the stock is cheap or expensive hinges on the expected recovery actually arriving. Read the fair value with that caveat.
The share trades about 13% below its 52-week high and 28% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 3% fair-value upside, at −77%, PRVA screens richer than that median.
Fair Value models
Bear$4.72Fair Value $5.52Bull$6.52
Price $24.42 · Downside -77.4%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then ($0.2230 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
In the last 6 months, 3 officers or directors sold shares worth $15.0M and none bought.
SaleDavid MountcastleEVP & Chief Financial Officer12× since Dec 12, 2025: 148,501 shares, avg. $25.07$3.7MJul 9, 2026
SaleMatthew Shawn MorrisDirector6× since Dec 12, 2025: 455,677 shares, avg. $26.07$11.9MJul 6, 202610b5-1 plan
SaleParth MehrotraChief Executive Officer, Director5× since Mar 6, 2026: 286,123 shares, avg. $22.46$6.4MMay 12, 2026
SaleEdward C FargisEVP & General Counsel9,343 shares at $22.99$214,756Mar 9, 2026
Plus 13 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.85/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+22.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+16.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+21.0%
Start year 2020 (pandemic)
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+18.2%
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−1.0%
Earnings growth per share plus dividend.
Earnings per share, growth per year−1.0%
Dividend (yield on the price)0.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.3% → 2%
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far and less than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+5.2%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+9.7%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +2.7% a year for the price and +7.2% for the forecasts.
News mood ⓘNews mood, the average tone of recent news (96 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Hype
Recent news coverage is unusually upbeat, far more positive than stocks are typically covered.
AI conclusion: Payer partnerships enable coordinated value-based care while independent physicians retain ownership, yet thin signals and low margins show limited evidence of durable advantage.
Main risk: Further state expansion risks exposing limits in consistent execution and would impair the ability to reach sufficient scale in risk arrangements.
Privia just renewed its Virginia agreement with Anthem to keep members in-network while pushing value-based care and lower costs. This aligns with the model of backing independent physicians through shared technology and coordination, all while they retain ownership and autonomy. Our models see the stock as overvalued. Will these payer ties deliver enough scale in risk arrangements, or will the push into more states expose limits in consistent execution?
Compare Privia Health Group Inc with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Health Information Services · 117 stocks
Beats the industry median on 5/13 measures
Overall it trails its industry peers.
Valuation
Quality Score59 · Above median
Fair Value upside−77.4% · Bottom 25%
Profitability
Return on equity (12 months)4.7% · Above median
Return on assets2.2% · Above median
Net margin (12 months)1.9% · Below median
Operating margin (12 months)3.1% · Below median
Growth and dividend
Revenue growth (quarter YoY)13.2% · Above median
Balance sheet
Debt / equity0.04× · Above median
Valuation Multiplesvs Health Information Services median · lower = cheaper
P/E (12 months)93.9× · Priciest 25%
P/B4.37× · Priciest 25%
P/S (12 months)1.71× · Cheaper than median
Price / free cash flow (fiscal year)25.8× · Pricier than median
EV/EBITDA56.3× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 5
FUTURE (revenue growth)66· sector 46
PAST (return on equity)19· sector 10
HEALTH (low debt)98· sector 98
DIVIDEND (yield)0· sector 41
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Privia Health Group Inc Fair Value". https://www.fairvalue-calculator.com/stock/PRVA
Frequently asked questions
Is Privia Health Group Inc (PRVA) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of $5.52 versus a price of $24.42, about 77% lower (overvalued).
What is the fair value of PRVA?
Our model-based fair value for Privia Health Group Inc is $5.52 (as of Nov 8, 2026), built from audited fundamentals. The current price: $24.42.
What is the quality score of PRVA?
Privia Health Group Inc has a Quality Score of 59/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Privia Health Group Inc (PRVA)?
Our model-based price target is the fair value of $5.52 (as of Nov 8, 2026) from 24 valuation models. Cautious scenario $4.72, optimistic scenario $6.52. It is a calculation from audited fundamentals, not an analyst target.
What is the Privia Health Group Inc stock forecast for 2026?
Our models put fair value at $5.52, about 77% lower versus a price of $24.42 (overvalued). Cautious scenario $4.72, optimistic scenario $6.52. The calculation is refreshed regularly with new filings.
What is the revenue of Privia Health Group Inc (PRVA)?
Privia Health Group Inc reported trailing-twelve-month revenue of about $2.4B (latest available figure, as of Nov 8, 2026).
What growth is priced into Privia Health Group Inc (PRVA)?
For today's price to be fair in a discounted-cash-flow model, Privia Health Group Inc would have to grow free cash flow by +5.2 % per year for five years (discount rate 9.1 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +21.0 % per year. As of Nov 8, 2026.
What discount rate (WACC) does the fair value of PRVA use?
Our models discount Privia Health Group Inc at 9.1 %: a base by market capitalisation (mid), damped by beta 0.75, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Privia Health Group Inc that is +5.2 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (9.1 %) and the same formula as our fair value.
How much growth has Privia Health Group Inc (PRVA) delivered so far?
Over the past 5 years revenue at Privia Health Group Inc grew +21.0 % a year. The price currently implies free-cash-flow growth of +5.2 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Privia Health Group Inc (PRVA) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Privia Health Group Inc (+5.2 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Privia Health Group Inc (PRVA)?
The free-cash-flow yield on the price is 5.04 %: that much free cash flow Privia Health Group Inc produces per unit of market value. When it exceeds the discount rate of our models (9.1 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Privia Health Group Inc (PRVA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Privia Health Group Inc it is $5.52 per share (as of Nov 8, 2026), against a price of $24.42. It is the blended result of 24 valuation models in 7 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Privia Health Group Inc stock overvalued or undervalued in 2026?
As of Nov 8, 2026, PRVA trades above its calculated fair value: price $24.42, fair value $5.52, a gap of about −77% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of PRVA?
No. The price is what the market pays today ($24.42); the fair value is what the company's own numbers justify ($5.52). For Privia Health Group Inc the two are $18.90 per share apart. That gap is exactly why we show both numbers side by side.
How much is Privia Health Group Inc worth?
The market values Privia Health Group Inc at about $3.2B (market capitalisation, as of Nov 8, 2026). Per share that is $24.42; our models calculate a fair value of $5.52 per share.
What do the bullish and bearish scenarios say about PRVA?
Our models span a range for Privia Health Group Inc: cautious scenario $4.72, base $5.52, optimistic $6.52 per share (as of Nov 8, 2026, price $24.42). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of PRVA?
Privia Health Group Inc trades at a price-to-earnings ratio of 93.9 (as of Nov 8, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $5.52 is built from several models across several years. Other multiples: P/B 4.4, P/S 1.7, EV/EBITDA 56.3.
How solid is the balance sheet of Privia Health Group Inc (PRVA)?
Balance-sheet figures for Privia Health Group Inc (as of Nov 8, 2026): return on equity 4.7%, debt of 0.04 per unit of equity. They feed the Quality Score of 59/100, which measures business quality independently of the share price.
How far is PRVA from its 52-week high?
Privia Health Group Inc trades at $24.42, about 13% below its 52-week high of $28.10 and 28% above the low of $19.10 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $5.52 is for.
Which stocks are comparable to Privia Health Group Inc?
From the same area (Healthcare) we also value Veeva Systems Inc, Pro Medicus Limited, BrightSpring Health Services, Inc, Hinge Health, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Privia Health Group Inc stock attractive at the current price?
The data as of Nov 8, 2026: price $24.42, calculated fair value $5.52 (−77%), Quality Score 59/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of PRVA calculated?
We run Privia Health Group Inc through 24 models from 7 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of $5.52 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Privia Health Group Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Privia Health Group Inc (PRVA)?
The closing price on Nov 6, 2026 was $24.42. Our model-based fair value is $5.52, about 77% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Privia Health Group Inc right now?
The price sits above even our optimistic bull case ($6.52). The favourable scenario is already priced in. Solid but not exceptional quality (59/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of Privia Health Group Inc
How large is the market capitalisation of Privia Health Group Inc (PRVA)?
The market capitalisation of Privia Health Group Inc is $3.2B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Privia Health Group Inc (PRVA)?
The price-to-sales ratio of Privia Health Group Inc is 1.71 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Privia Health Group Inc (PRVA)?
Earnings per share at Privia Health Group Inc are $0.2600 (price ÷ EPS = P/E 93.9). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Privia Health Group Inc (PRVA)?
The net margin of Privia Health Group Inc is 1.4% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Privia Health Group Inc (PRVA)?
The return on equity (ROE) of Privia Health Group Inc is 4.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Privia Health Group Inc (PRVA)?
On an EBIT basis the return on assets of Privia Health Group Inc is −5.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Privia Health Group Inc (PRVA)?
The operating margin of Privia Health Group Inc is 3.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Privia Health Group Inc (PRVA)?
Revenue at Privia Health Group Inc is growing +13.2% versus a year earlier (3y avg +16.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Privia Health Group Inc (PRVA)?
Earnings per share at Privia Health Group Inc are growing +100% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Privia Health Group Inc (PRVA) hold?
Privia Health Group Inc holds more cash than debt, $470M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Privia Health Group Inc in the live analysis
One click puts Privia Health Group Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 8, 2026